Results 241 to 250 of about 31,985 (308)

Hexahydroquinoline Featuring Amide Functionality: A Promising Scaffold With Calcium Channel Blocking Activity

Drug Development Research, Volume 87, Issue 2, April 2026.
ABSTRACT Hexahydroquinoline (HHQ) is a widely recognized scaffold that has garnered considerable attention owing to its diverse pharmacological properties. The structure of HHQ includes a 1,4‐dihydropyridine (DHP) ring, which serves as the pharmacophore for the predominant class of drugs known as calcium channel blockers.
Ebru Koçak Aslan, Kevin Lam, Sun Huang, Göknil Pelin Coşkun, Ayşe Karagüzel, Katrin Denzinger, Kaan Birgül, Mert Ülgen, Jordan W. Nafie, Onur Şahin, Daniel W. Armstrong, Gerald W. Zamponi, Gerhard Wolber, Miyase Gözde Gündüz   +13 more
wiley   +1 more source

The cannabinoid CB₂ receptor positive allosteric modulator EC21a exhibits complicated pharmacology <i>in vitro</i>. [PDF]

J Recept Signal Transduct Res
Qi A, Han X, Quitalig M, Wu J, Christov PP, Jeon K, Jana S, Kim K, Engers DW, Lindsley CW, Rodriguez AL, Niswender CM.   +11 more
europepmc   +1 more source

Hydroxyl radical footprinting modification reveals an intradomain communication pathway in EFL1 disrupted by a Shwachman‐Diamond syndrome‐associated mutation

Protein Science, Volume 35, Issue 4, April 2026.
Abstract Shwachman‐Diamond syndrome (SDS) is a rare genetic disorder characterized by pancreatic insufficiency and neutropenia. While most cases are linked to mutations in the SBDS gene, some involve mutations in the GTPase EFL1. This protein works with SBDS to release the anti‐association factor eIF6 from the 60S ribosomal subunit during ribosome ...
Jonathan A. Zúñiga‐Domínguez, Rohit Jain, Martín González‐Andrade, Erik R. Farquhar, Mark R. Chance, Abril Gijsbers, Nuria Sánchez‐Puig   +6 more
wiley   +1 more source

Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M₄ Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM). [PDF]

ACS Chem Neurosci
Engers JL, Baker LA, Chang S, Luscombe VB, Rodriguez AL, Niswender CM, Cho HP, Bubser M, Gray AT, Jones CK, Peng W, Rook JM, Bridges TM, Boutaud O, Conn PJ, Engers DW, Lindsley CW, Temple KJ.   +17 more
europepmc   +1 more source

AI‐assisted design of a VEGFR2 agonistic peptide that promotes angiogenesis and wound repair

Protein Science, Volume 35, Issue 4, April 2026.
Abstract Vascular endothelial growth factor (VEGF) serves as a principal regulator of neovascularization and is essential for vascular regeneration. In this study, we identified and evaluated VEGF Mimetic Peptide3 (VMP3), a novel synthetic peptide developed as a potential VEGFR‐2/VEGF‐A modulator.
Farzana Yasmeen, Rajath Ramachandran, Rameez Hassan Pirzada, Bogeum Choi, Hana Seo, Wook Kim, Moon Suk Kim, Sangdun Choi   +7 more
wiley   +1 more source

Network Pharmacology Combined With Clinical Retrospective Analysis to Investigate the Potential Mechanisms and Clinical Significance of Folate in Treating Spinal Cord Injury

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
ABSTRACT Folate is an indispensable nutrient involved in key biological processes, including enzymatic reactions, DNA replication, metabolic regulation, and methylation. Studies indicate that folate promotes neuronal regeneration and repair in patients with spinal cord injury (SCI); however, its precise mechanisms remain unclear.
Xiaolei Chu, Jiajia Liang, Jiaojiao Sun, Wenjie Liu, Lei Zhang, Zheng Xing, Qingwen Li, Qi Li   +7 more
wiley   +1 more source

Effect of intrahippocampal microinjection of VU0155041, a positive allosteric modulator of mGluR4, on long term potentiation in a valproic acid-induced autistic male rat model. [PDF]

IBRO Neurosci Rep
Ebrahimi Z, Gholipour P, Mohammadkhani R, Ghahremani R, Sarihi A, Komaki A, Salehi I, Karimi SA.   +7 more
europepmc   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, Volume 183, Issue 7, Page 1364-1389, April 2026.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.

JAMA Neurol
Shanbhag NM, Padmanabhan JL, Zhang Z, Harel BT, Jia H, Kangarloo T, Yin W, Dowling AV, Laurenza A, Khudyakov P, Galinsky K, Latzman RD, Simuni T, Weintraub D, Horak FB, Lustig C, Maruff P, Simen AA.   +17 more
europepmc   +1 more source